SP 1FOR ACNE DISEASE
Lactobacillus rhamnosus is the most studied probiotic bacterium among lactobacilli.
L. rhamnosus SP 1 AND ACNE
It has been estimated that in 2010 around 650 million people worldwide were affected by acne, about 9.4% of the population. Acne is extremely common in individuals between 12 and 25 years and is globally distributed.Acne is a chronic inflammatory disorder characterised by a number of different skin lesions, including comedones as well as painful and inflamed pustules.
L. rhamnosus SP 1 normalises skin expression of genes implicated in insulin signalling and improves adult acne.
TECHNICAL INFORMATION
IDENTIFICATION16S rDNA gene sequence analysis (species characterization),PFGE (strain characterization)L. rhamnosus SP 1's PFGE profile is equivalent toL. rhamnosus LGG (ATCC53103)Also the complete genome is available
SAFETYincluded in EFSA QPS list (EFSA Journal 2017)absence of investigated antibiotic resistancegenes (EFSA Journal 2012; 10(6):2740)
BSE/TSE free
GMO free
Colorant free and hypoallergenic(list of allergens in compliance with Reg. UE 1169/2011)
STRAIN DEPOSIT NUMBERDSM 21690
STABILITY (Log10 cfu/g)
SHELF LIFE18 months at temperature <-18°C12 months at temperature 5±3°C
SURVIVAL DURINGGASTROINTESTINAL TRANSIT
Acid tolerance Bile tolerance
Simulated gastric juice Simulated pancreatic juice
95%
9,5
11,5
12,0
9,0
11,0
8,5
10,5
8,0
10,0
0 4010 20 30
Cel
l cou
nts
(Log
10 c
fu/g
)
Time (months)
-20°C
20% reduction
1 log reduction
5°C
Sacco System is the new international biotech centre for innovation in nutraceutical and pharmaceutical products. Sacco System provides its customers with healthy, natural and functional products.We can offer a flexible service, develop formulation into adopted dosage forms, toll manufacturing (from laboratory to pilot production) and partnership for the development, production and the sale of single or mix probiotic strains of property or patented.
Download onApple Store & Google Play saccosystem.com
CLINICAL STUDYDouble blinded, placebo-controlled, randomised study
REFERENCES: Fabbrocini G., et al.; Supplementation with Lactobacillus rhamnosus SP 1 normalises skin expression of genes implicated in insulin signalling and improves adult acne. Benef Microbes. 2016
RESULTS
The phatogenesis of inflammatory acne is complex and involves:
• Increased sebum production
• Hyperplasia of the sebaceous glands under androgenic influence
• Ductal obstruction from increase keratinocyte desquamation and proliferation
• Propionibacterium acne colonisation
• Inflammatory cell infiltration
Alterations in insulin signalling may play a significant role in the pathogenesis of acne:
Insulin and insulin-like growth factor-1 (IGF1) have been shown to exert acne promoting actions: IGF1 stimulates both sebaceous lipogenesis and androgen receptor signalling by promoting nuclear extrusion of the androgen receptor through the box transcription factor 01 (FOX01). Downregulation of nuclear FOX01 expression promotes lipogenesis, upregulation of inflammatory cytokines, increased kerationocyte proliferation.
Probiotics may act as modulators of the gut-skin axis: L. rhamnosus SP 1 has been shown to enhance insulin sensitivity as well as reduce lipogenesis in experimental animals.
Adults with activeinflammatory acne
20
Daily dose
3x109
CFU/day weeks12
Interventionperiod
Adults age
30-37Age
3
2,5
2
1,5
1
0,5
0
IGF1 Placebo group IGF1 Probiotic group FOX01 Placebo grouo FOX01 Probiotic grouo
baseline 12 week Appearance of acne
2,24% 2,11% 2,31%
0,86%
0,081%
1,56%
0,9% 1,34%
Improved appearance of acne in adult patiens
32% reduction IGF1 (P<0,001) 65% increase FOX01 (P<0,001)
Change in relative gene expression values of IGF1 and FOX01 in skin biopsies